GLP-1 medications and related compounds

Semaglutide

An FDA-approved GLP-1 receptor agonist active ingredient used in prescription products for label-defined indications.

WegovyOzempicRybelsusGLP-1 receptor agonist

Concise answer

What is Semaglutide?

Semaglutide is the active ingredient in FDA-approved prescription products. It has strong human trial evidence for approved uses, but unapproved or compounded versions are not FDA-approved.

Definition

What It Is

Semaglutide is a GLP-1 receptor agonist active ingredient. On PeptideWars, it is treated differently from research peptides because FDA-approved prescription products exist and have label-defined safety information.

Status

Legal and Regulatory Notes

FDA: FDA-approved in specific prescription products and indications. Product labels, eligibility, risks, and monitoring should be reviewed with a licensed clinician.
Research: Large randomized human trials and current FDA labeling support approved uses. Evidence does not validate unapproved versions or non-label marketing claims.
Sport: Not categorized here as a peptide-doping research compound; athletes should still check sport medication rules.

Research map

How Semaglutide Is Being Studied

Weight management under approved product labelingType 2 diabetes products and glycemic outcomesCardiometabolic outcomes in selected populationsSafety issues around unapproved compounded GLP-1 products

People

Human Research

Large human trials, including STEP 1, support semaglutide's effect on body weight in trial populations when used with lifestyle intervention under clinical supervision.

Models

Animal and Cell Research

Preclinical data helped develop the drug class, but PeptideWars prioritizes FDA labeling and randomized human trials for this page.

Safety

Known Risks and Side Effects

Gastrointestinal adverse effects are common in trials and labeling
Label warnings and contraindications require clinician review
Medication errors and salt-form issues have been flagged by FDA for unapproved GLP-1 products
Not appropriate for everyone; medical history and other medications matter

Compliance

Interpretation Guardrails

FDA-approved semaglutide products are not the same thing as unapproved online, research-use, or compounded products.
FDA warns that compounded drugs are not FDA-approved and may carry quality, dosing, and ingredient-form risks.
Talk to a licensed clinician about any GLP-1 medication decision.

Internal links

Related Battles and Profiles

Battle Tirzepatide vs Semaglutide Two FDA-approved incretin active ingredients compared on evidence, approved-product status, safety, and regulatory cautions. Profile Tirzepatide An FDA-approved prescription active ingredient with dual GIP and GLP-1 receptor agonist activity in approved products. Profile Tesamorelin An FDA-approved GHRH analog product for a specific HIV-associated lipodystrophy indication. Guide Weight Management Peptides Separate FDA-approved incretin medications from research peptides and cosmetic weight-loss hype. Guide GLP-1 Medications and Related Compounds Approved medicines, compounded versions, counterfeit risk, and research compounds separated clearly.

FAQ

Common Questions

Is semaglutide FDA-approved?

Specific semaglutide products are FDA-approved for specific indications. The active ingredient alone, especially in unapproved products, should not be treated as equivalent to an approved product.

Is compounded semaglutide FDA-approved?

No. FDA states that compounded drugs are not FDA-approved and has raised concerns about unapproved GLP-1 drugs used for weight loss.

Does PeptideWars provide semaglutide dosing?

No. This site does not provide dosing protocols. Product-specific treatment decisions belong with a licensed clinician and official labeling.

Sources

Citations and Official References

Editorial Review

Written by the PeptideWars Editorial Team. Medical reviewer placeholder: licensed clinician review should be completed before production launch. Last updated May 6, 2026.